L7 Informatics

L7 Informatics, founded as Lab7 Systems in 2012, provides unified science platform software for life sciences organizations. Its product, L7|ESP (Enterprise Science Platform), is an AI-ready unified platform integrating MES (Manufacturing Execution System), LIMS (Laboratory Information Management System), ELN (Electronic Lab Notebook), and Scheduling capabilities into a single system.

Founded by CEO Vasu Rangadass and co-founder Chris Mueller, the company is headquartered in Austin, Texas, with 151 employees. It has raised $55M–$59.2M in total funding, including a $38M Series C round in June 2022 led by Banneker Partners with participation from Phoenix Venture Partners. Annual revenue is estimated at $15M–$23.8M as of 2025.

L7 Informatics serves life sciences organizations exclusively: pharmaceutical manufacturers, biotech companies, cell and gene therapy developers, and CDMOs. Its unified data model eliminates data silos between manufacturing, quality, and laboratory operations, supporting workflows for processes such as personalized medicine and cell therapy manufacturing.

Named customers include Gradalis, Cellipont Bioservices, Cellares, QIAGEN, GeneDx, Dana-Farber Cancer Institute, and Vernal Biosciences. The company has been named to the Deloitte Technology Fast 500 for four consecutive years and received the Frost & Sullivan Frost Radar Top Innovator 2025 award for Pharma/Biotech LIMS, with an Innovation Index of 4.85.

L7|ESP is designed for FDA 21 CFR Part 11 compliance and GxP-regulated pharmaceutical manufacturing environments, providing Electronic Batch Records, Master Batch Records, configurable e-signatures, Chain of Identity/Chain of Custody tracking, and validation support.

L7 Informatics focuses exclusively on life sciences, with 100% of its business serving pharmaceutical, biotechnology, and cell and gene therapy organizations. The company was built for life sciences manufacturing and R&D operations.

The company serves pharmaceutical manufacturers, biotech companies, cell and gene therapy developers, CDMOs (Contract Development and Manufacturing Organizations), and life sciences research institutions. Named customers include Gradalis, Cellipont Bioservices, Cellares, QIAGEN, GeneDx, Dana-Farber Cancer Institute, and Vernal Biosciences.

L7 Informatics has particular strength in emerging therapeutic modalities, including cell therapy, gene therapy, and personalized medicine manufacturing. Its unified data model and Chain of Identity/Chain of Custody tracking are designed for the complex workflows in these advanced therapy segments.

The company provides validation documentation and support for GxP environments. The platform is designed for FDA 21 CFR Part 11 compliance, with configurable e-signatures, audit trails, and Electronic Batch Record capabilities. The company's case studies describe successful FDA inspections and regulatory compliance at named customers.

All customers are in the life sciences sector; the company does not serve other industries. Whether it specifically serves medical device manufacturers or generic drug manufacturers is unstated; the platform's capabilities support these segments.

L7 Informatics has raised $55M–$59.2M in total funding; the figure varies by source. Its most recent round was a $38M Series C in June 2022, led by Banneker Partners with participation from Phoenix Venture Partners.

Annual revenue is estimated at $15M–$23.8M as of 2025, based on multiple industry data sources; the company does not publish exact revenue figures. The range reflects differing reporting methodologies and timeframes across sources.

The company is privately held. Profitability and cash flow status are undisclosed, as is enterprise value. There has been no acquisition or M&A activity; the company remains independent.

L7 Informatics sells one unified product, L7|ESP (Enterprise Science Platform), integrating four core applications into a single system: L7 MES (Manufacturing Execution System), L7 LIMS (Laboratory Information Management System), L7 ELN (Electronic Lab Notebook), and L7 Scheduling. The platform uses a single data model across all modules, eliminating data silos between manufacturing, quality, and laboratory operations.

L7 MES provides Electronic Batch Records (EBR), Master Batch Records, Recipe Management, Bill of Materials, Sample Plan Management, Quality Review, configurable e-signatures, Label Reconciliation, and automatic batch report generation. The system maintains Chain of Identity (CoI) and Chain of Custody (CoC) tracking throughout the manufacturing process.

The platform is cloud-based (SaaS) and marketed as "AI-ready" to support future machine learning and predictive analytics capabilities. It includes bi-directional SAP integration, process equipment integration, and instrument connectors for automated data acquisition. AI/ML features are positioned as future capabilities rather than current offerings.

Mobile apps for iOS or Android are unstated.

L7 Informatics has a technology partnership with SAP: L7|ESP offers bi-directional SAP integration to synchronize manufacturing and quality data with enterprise resource planning systems. Process equipment integration partnerships connect the platform with manufacturing equipment from various vendors.

The platform is cloud-based and runs on major cloud infrastructure providers; specific AWS, Azure, or Google Cloud partnerships are undisclosed. Industry affiliations, consulting partner networks, and systems-integrator partnerships are undisclosed. Implementation and consulting services are delivered by the company's internal team rather than through a partner network.

ISPE (International Society for Pharmaceutical Engineering) membership and other industry association affiliations are undisclosed. No FDA partnership or collaboration is disclosed.

L7 Informatics provides implementation, validation, and ongoing support services for L7|ESP customers, including validation documentation and support for GxP environments to help customers achieve FDA 21 CFR Part 11 compliance.

Implementation services include platform configuration, workflow setup, SAP integration (where applicable), equipment integration, user training, and validation support. The company's case studies describe a 30% reduction in data handling time for CDMO operations.

Support regions, 24/7 support availability, support SLAs, and dedicated support contact channels are undisclosed.

Training is provided as part of implementation; specific training programs, certification programs, and learning management systems are undisclosed. Professional services are delivered by L7 Informatics staff rather than through a partner network.

User community forums, user conferences, and customer events are undisclosed. Resource center content (whitepapers, webinars, case studies) is limited on the public website.

L7 Informatics was named to the Deloitte Technology Fast 500 list for four consecutive years, an award recognizing rapid revenue growth and innovation in the technology sector.

L7 Informatics received the Frost & Sullivan Frost Radar Top Innovator 2025 award for Pharma/Biotech LIMS, with an Innovation Index score of 4.85 out of 5.

Founder and CEO Vasu Rangadass has led the company since its 2012 founding, over 13 years. Co-founder Chris Mueller remains with the company.

ISO 9001, ISO 27001, and SOC 2 certifications are undisclosed. No Gartner Magic Quadrant positioning or Forrester Wave recognition is evidenced.

The company's case studies describe measurable outcomes and regulatory compliance successes.

The corporate website (l7informatics.com) features customer case studies, product information, and company news. The company publishes press releases for funding rounds and industry awards.

An active LinkedIn company page exists (linkedin.com/company/l7-informatics); follower count and engagement metrics are undisclosed behind LinkedIn's login gate. A Twitter/X handle or other social media channel is undisclosed.

Content marketing includes customer case studies describing measurable outcomes, including a claimed 30% reduction in data handling time for CDMO operations. Product demos are available through the "Request Demo" option on the website. Free trial availability is undisclosed. Resource center content (whitepapers, webinars, videos) is limited on the public site.

Site content uses life sciences-specific terminology and use cases.